FibroBiologics Inc. (NASDAQ:FBLG - Get Free Report) General Counsel Ruben Garcia purchased 40,000 shares of the business's stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $0.33 per share, with a total value of $13,200.00. Following the acquisition, the general counsel directly owned 180,000 shares in the company, valued at $59,400. This represents a 28.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
FibroBiologics Price Performance
NASDAQ:FBLG opened at $0.42 on Tuesday. The company has a market cap of $28.36 million, a price-to-earnings ratio of -1.00 and a beta of -0.69. FibroBiologics Inc. has a 1 year low of $0.22 and a 1 year high of $1.53. The stock's 50 day simple moving average is $0.29 and its two-hundred day simple moving average is $0.39.
FibroBiologics (NASDAQ:FBLG - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.06. As a group, analysts anticipate that FibroBiologics Inc. will post -0.53 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on FBLG. Weiss Ratings restated a "sell (e+)" rating on shares of FibroBiologics in a report on Thursday, January 22nd. HC Wainwright dropped their price target on FibroBiologics to $4.00 and set a "buy" rating for the company in a research report on Thursday. Finally, D. Boral Capital reduced their price objective on FibroBiologics from $15.00 to $7.00 and set a "buy" rating on the stock in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, FibroBiologics presently has a consensus rating of "Hold" and an average price target of $5.50.
Get Our Latest Analysis on FBLG
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of FibroBiologics during the 4th quarter worth approximately $34,000. Renaissance Technologies LLC grew its position in FibroBiologics by 287.3% in the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company's stock valued at $52,000 after acquiring an additional 171,800 shares during the last quarter. Geode Capital Management LLC increased its stake in FibroBiologics by 20.7% in the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company's stock worth $78,000 after purchasing an additional 59,813 shares during the period. AMG National Trust Bank purchased a new stake in FibroBiologics in the fourth quarter worth $31,000. Finally, Yorkville Advisors Global LP bought a new stake in shares of FibroBiologics during the third quarter worth $278,000.
FibroBiologics Company Profile
(
Get Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
